menu search

CYT / Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript

Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript
Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript Read More
Posted: Mar 16 2022, 20:14
Author Name: Seeking Alpha
Views: 041386

CYT News  

Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise

By Seeking Alpha
September 18, 2023

Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise

Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 in more_horizontal

Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 16, 2022

Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript

Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript more_horizontal

Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

By Business Wire
March 9, 2022

Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next- more_horizontal


Search within

Pages Search Results: